Fig. 7

HDAC inhibitor ITF2357 reduces the resistance of mut-KRAS NSCLC to Pem by inhibiting HDAC2/miR-130a-3p/Rad51 in vivo. A The changes of tumor size in mice upon different treatments. B Tumor weight analysis of mice upon different treatments. C RT-qPCR was used to detect the gene expression levels of HDAC2, miR-130a-3p and Rad51 in tumor tissues of mice upon different treatments. D Immunohistochemistry and in situ hybridization were used to determine the expression levels of HDAC2, Rad51 and miR-130a-3p in tumor tissues of mice upon different treatments. E The protein expression levels of HDAC2 and Rad51 in tumor tissues of mice upon different treatments were detected by Western blot. There were 5 mice in each group. ****p < 0.0001. Data between two groups were compared by unpaired t test. Data among multiple groups were compared by one-way ANOVA, followed by Tukey’s post hoc tests. Data among multiple groups at different time points were compared by repeated measures ANOVA, followed by Bonferroni post hoc tests